A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BASE
Most Recent Events
- 02 Aug 2022 Results assessing antiretroviral concentrations in dried blood spots (DBS) to compare with viral suppression (VS) at 24 weeks (W24) post Bictegravir/emtricitabine/tenofovir alafenamide initiation, presented at the 24th International AIDS Conference.
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 09 Jun 2021 Status changed from recruiting to active, no longer recruiting.